Angiotensin II receptor / HMG-CoA reductase

Class

ARB + statin fixed-dose combination

This mechanism combines two independent cardiovascular drug actions in a single fixed-dose product. The first component blocks the angiotensin II receptor (specifically the AT1 subtype), a G-protein-coupled receptor that, when activated by the hormone angiotensin II, causes blood vessels to constrict and promotes sodium and fluid retention, raising blood pressure. Blocking this receptor lowers blood pressure and reduces strain on the heart and vasculature. The second component inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis within the liver, which lowers circulating low-density lipoprotein (LDL) cholesterol. Elevated blood pressure and elevated LDL cholesterol are two distinct, well-established risk factors for atherosclerosis, heart attack, and stroke. Combining an angiotensin receptor blocker (ARB) with a statin in one pill addresses both risk factors simultaneously rather than requiring separate prescriptions. This fixed-dose approach is used broadly in the management of patients who have both hypertension and dyslipidemia, conditions that frequently coexist and compound cardiovascular risk. The rationale for pairing these particular mechanisms, rather than using either alone, is that blood pressure and cholesterol act through largely independent pathological routes toward vascular disease, so treating both together produces a more comprehensive reduction in overall cardiovascular risk than either alone.